LTFS
ARLZ

Ladenburg Thalmann Financial Services’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,004
Closed -$9K – 5608
2018
Q2 		$9K Hold
6,004
– – ﹤0.01% 4346
2018
Q1 		$9K Hold
6,004
– – ﹤0.01% 4346
2017
Q4 		$8K Hold
6,004
– – ﹤0.01% 4348
2017
Q3 		$14K Sell
6,004
-27
-0.4% -$36 ﹤0.01% 3923
2017
Q2 		$8K Buy
6,031
+5,965
+9,038% +$8.62K ﹤0.01% 4175
2017
Q1 		$0 Hold
66
– – ﹤0.01% 5170
2016
Q4 		$0 Buy
66
+27
+69% +$128 ﹤0.01% 5139
2016
Q3 		$0 Hold
39
– – ﹤0.01% 5093
2016
Q2 		$0 Buy
+39
New +$147 ﹤0.01% 5075

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Ladenburg Thalmann Financial Services's ARLZ Position: Q3 2018 in Review

Ladenburg Thalmann Financial Services sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 6,004 shares — an estimated $9K sold.

Ladenburg Thalmann Financial Services first reported a position in ARLZ in Q2 2016 and held it in 9 quarters. The position peaked at $14K in Q3 2017. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • Ladenburg Thalmann Financial Services reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 6,004 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $9K.
  • Ladenburg Thalmann Financial Services first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 9 quarters.
  • Ladenburg Thalmann Financial Services's Aralez Pharmaceuticals Inc. position peaked at $14K in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2018, filed 14 Nov 2018.